177 related articles for article (PubMed ID: 32389672)
61. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
[TBL] [Abstract][Full Text] [Related]
62. Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.
Decourt A; Gondouin B; Delaroziere JC; Brunet P; Sallée M; Burtey S; Dussol B; Ivanov V; Costello R; Couchoud C; Jourde-Chiche N
Clin J Am Soc Nephrol; 2016 Mar; 11(3):431-41. PubMed ID: 26728585
[TBL] [Abstract][Full Text] [Related]
63. Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Kourelis TV; Gertz M; Zent C; Lacy M; Kyle R; Kapoor P; Zeldenrust S; Buadi F; Witzig T; Hayman S; Lust J; Russell S; Lin Y; Rajkumar VS; Kumar S; Leung N; Dingli D; Dispenzieri A
Am J Hematol; 2013 May; 88(5):375-8. PubMed ID: 23508840
[TBL] [Abstract][Full Text] [Related]
64. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Wong SW; Hegenbart U; Palladini G; Shah GL; Landau HJ; Warner M; Toskic D; Jaccard A; Hansen T; Bladé J; Cibeira MT; Kastritis E; Dispenzieri A; Wechalekar A; Varga C; Schönland SO; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e493-e499. PubMed ID: 30104177
[TBL] [Abstract][Full Text] [Related]
65. Primary (AL) amyloidosis in plasma cell disorders.
Müller AM; Geibel A; Neumann HP; Kühnemund A; Schmitt-Gräff A; Böhm J; Engelhardt M
Oncologist; 2006; 11(7):824-30. PubMed ID: 16880241
[TBL] [Abstract][Full Text] [Related]
66. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
67. Characteristics and long-term outcome of patients with systemic immunoglobulin light-chain amyloidosis.
Nelson LM; Gustafsson F; Gimsing P
Acta Haematol; 2015; 133(4):336-46. PubMed ID: 25531398
[TBL] [Abstract][Full Text] [Related]
68. The Coexistence of Multiple Myeloma-associated Amyloid Light-chain Amyloidosis and Fabry Disease in a Hemodialysis Patient.
Taguchi K; Moriyama A; Kodama G; Nakayama Y; Fukami K
Intern Med; 2017; 56(7):841-846. PubMed ID: 28381753
[TBL] [Abstract][Full Text] [Related]
69. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
70. Incidence and impact of light chain associated (AL) amyloidosis on the prognosis of patients with multiple myeloma treated with autologous transplantation.
Desikan KR; Dhodapkar MV; Hough A; Waldron T; Jagannath S; Siegel D; Barlogie B; Tricot G
Leuk Lymphoma; 1997 Oct; 27(3-4):315-9. PubMed ID: 9402328
[TBL] [Abstract][Full Text] [Related]
71. Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation.
Pun SC; Landau HJ; Riedel ER; Jordan J; Yu AF; Hassoun H; Chen CL; Steingart RM; Liu JE
J Am Soc Echocardiogr; 2018 Jan; 31(1):64-70. PubMed ID: 29111123
[TBL] [Abstract][Full Text] [Related]
72. [Long-term survival of a patient with multiple myeloma-associated severe cardiac AL amyloidosis after implantation of a cardioverter-defibrillator].
Mori M; Kitagawa T; Sasaki Y; Onaka T; Yonezawa A; Morimoto H; Haratake J; Imada K
Rinsho Ketsueki; 2014 Apr; 55(4):450-5. PubMed ID: 24850457
[TBL] [Abstract][Full Text] [Related]
73. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
[TBL] [Abstract][Full Text] [Related]
74. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
[TBL] [Abstract][Full Text] [Related]
75. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement.
Dietrich S; Schönland SO; Benner A; Bochtler T; Kristen AV; Beimler J; Hund E; Zorn M; Goldschmidt H; Ho AD; Hegenbart U
Blood; 2010 Jul; 116(4):522-8. PubMed ID: 20375312
[TBL] [Abstract][Full Text] [Related]
76. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis.
Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J;
Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382
[TBL] [Abstract][Full Text] [Related]
77. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis.
Seldin DC; Choufani EB; Dember LM; Wiesman JF; Berk JL; Falk RH; O'Hara C; Fennessey S; Finn KT; Wright DG; Skinner M; Sanchorawala V
Clin Lymphoma; 2003 Mar; 3(4):241-6. PubMed ID: 12672274
[TBL] [Abstract][Full Text] [Related]
78. Nephrotoxic potential of Bence Jones proteins.
Solomon A; Weiss DT; Kattine AA
N Engl J Med; 1991 Jun; 324(26):1845-51. PubMed ID: 1904132
[TBL] [Abstract][Full Text] [Related]
79. The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantation.
Leung N; Kumar SK; Glavey SV; Dispenzieri A; Lacy MQ; Buadi FK; Hayman SR; Dingli D; Kapoor P; Zeldenrust SR; Russell SJ; Lust JA; Hogan WJ; Rajkumar SV; Gastineau DA; Kourelis TV; Lin Y; Gonsalves WI; Go RS; Gertz MA
Nephrol Dial Transplant; 2016 Aug; 31(8):1284-9. PubMed ID: 26627634
[TBL] [Abstract][Full Text] [Related]
80. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.
Palladini G; Lavatelli F; Russo P; Perlini S; Perfetti V; Bosoni T; Obici L; Bradwell AR; D'Eril GM; Fogari R; Moratti R; Merlini G
Blood; 2006 May; 107(10):3854-8. PubMed ID: 16434487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
